Moreover, in vitro treatment with Manzamine A reduced the metastatic potential of AsPC-1 pancreatic cancer cells and sensitized them to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis via GSK-3β blockade [54], suggesting that GSK-3β inhibitors may be effectively combined with TRAIL to treat pancreatic cancer [55]. Here, GSK3B is linked to pancreatic neoplasm.